TELA Bio to Announce First Quarter 2025 Financial Results
Rhea-AI Summary
TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring management discussions on financial performance and corporate updates.
Interested investors must register for the conference call at least 15 minutes before it begins. The event will be accessible through a live webcast and replay via the Events & Presentations section of TELA's investor website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TELA declined 6.92%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
First Quarter Earnings Conference Call and Webcast Details
Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the Events & Presentations page of the investor section of TELA's website.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
When will TELA Bio release its Q1 2025 earnings report?
How can investors participate in TELA Bio's Q1 2025 earnings call?
What is TELA Bio's main business focus?
What stock exchange is TELA Bio listed on?
